NasdaqGS:CERTHealthcare Services
Certara (CERT) Stock Price Faces Loss Pressure Despite Software Gains
Certara entered this earnings report with the stock up strongly over the past three months, then gave back 4.7% to close at US$7.80 after the Q2 release. The selloff contrasts with the core thesis that this is a steadily improving software driven drug development platform.
The headline this quarter is not revenue growth. It is the tension between healthy profitability on an adjusted basis and continuing losses under generally accepted accounting principles. Certara delivered US$93.3m in...